In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to GBP200 million impact on HIV sales in 2025. GSK PLC (NYSE:GSK) adjusted its ...

Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to ...

Who Are The Major Players In The Shingrix Zostavax Market? As the market expands, major companies such as GSK plc are capitalizing on this robust growth. GSK plc remains a dominant force in the ...

GSK blames political and regulatory pressures for the decline in its vaccine’s business in 2024, as it expects sales to further shrink in 2025. Despite these challenges, GSK beat Q4 2024 ...

the partnership with Zhifei positions GSK for long-term success. Richard Parkes, BNPP Exane: Inquired about peak sales potential for Arexvy and Shingrix. Dame Emma Walmsley emphasized confidence ...

Shingrix and our vaccines pipeline will contribute meaningfully in the medium and long term. Importantly, 2025 will see further additions to GSK's portfolio with five new product approvals ...

Shingrix 是一款重组带状疱疹疫苗，2024 年以 33.64 亿英镑（+1%）的收入继续稳坐全球疫苗大品种的宝座。GSK 在财报中披露，Shingrix 中国销售额下降。 好在脑膜炎疫苗Meningitis（包括 Bexsero 和 Menveo ）增长强劲，为 GSK 疫苗板块注入了新的动力，2024 年斩获了 14.37 亿 ...